XTX Topco Ltd Sells 24,777 Shares of DURECT Co. (NASDAQ:DRRX)

XTX Topco Ltd reduced its position in DURECT Co. (NASDAQ:DRRX) by 52.7% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,240 shares of the specialty pharmaceutical company’s stock after selling 24,777 shares during the period. XTX Topco Ltd owned approximately 0.07% of DURECT worth $29,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of DRRX. International Assets Investment Management LLC lifted its stake in shares of DURECT by 41.3% in the second quarter. International Assets Investment Management LLC now owns 21,550 shares of the specialty pharmaceutical company’s stock valued at $28,000 after buying an additional 6,300 shares in the last quarter. Accredited Investors Inc. bought a new position in DURECT in the 2nd quarter valued at about $113,000. Gagnon Securities LLC boosted its stake in DURECT by 6.0% during the 1st quarter. Gagnon Securities LLC now owns 380,131 shares of the specialty pharmaceutical company’s stock valued at $460,000 after purchasing an additional 21,425 shares during the last quarter. Tocqueville Asset Management L.P. increased its holdings in DURECT by 10.8% during the 1st quarter. Tocqueville Asset Management L.P. now owns 256,220 shares of the specialty pharmaceutical company’s stock worth $310,000 after purchasing an additional 25,000 shares in the last quarter. Finally, Richmond Brothers Inc. raised its stake in shares of DURECT by 48.2% in the first quarter. Richmond Brothers Inc. now owns 768,344 shares of the specialty pharmaceutical company’s stock worth $930,000 after purchasing an additional 250,050 shares during the last quarter. 28.03% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

DRRX has been the subject of several recent research reports. HC Wainwright reiterated a “neutral” rating on shares of DURECT in a report on Thursday, September 26th. StockNews.com started coverage on shares of DURECT in a report on Wednesday. They set a “sell” rating on the stock.

DURECT Stock Down 1.5 %

DURECT stock opened at $1.34 on Thursday. DURECT Co. has a 52 week low of $0.47 and a 52 week high of $3.14. The company’s 50 day moving average price is $1.43 and its two-hundred day moving average price is $1.30. The stock has a market cap of $41.59 million, a P/E ratio of -1.41 and a beta of 1.14.

DURECT (NASDAQ:DRRX) last released its earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.05. The company had revenue of $2.17 million during the quarter, compared to analyst estimates of $2.49 million. DURECT had a negative return on equity of 261.43% and a negative net margin of 187.80%. During the same period in the prior year, the company posted ($0.46) earnings per share. On average, equities analysts anticipate that DURECT Co. will post -0.8 EPS for the current year.

About DURECT

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.